<DOC>
	<DOCNO>NCT03068650</DOCNO>
	<brief_summary>Celldex endeavor make investigational product available patient life-threatening disease exhaust treatment option reasonable expectation benefit risk . Requests expand access rindopepimut patient EGFRvlll express recurrent glioblastoma consider .</brief_summary>
	<brief_title>Expanded Access ( Compassionate Use ) Treatment Protocol Rindopepimut</brief_title>
	<detailed_description />
	<criteria>The patient histologically confirm relapsed recurrent GBM . EGFRvIII expression tumor tissue , assessed central laboratory use Celldex assay . Prior plan therapy must include standard chemoradiation temozolomide , unless patient candidate . Systemic corticosteroid therapy taper less 4 mg dexamethasone ( equivalent ) per day . The patient know allergy hypersensitivity KLH , GMCSF yeast derive product , history anaphylactic reaction shellfish protein . The patient abnormal organ function , active autoimmune disease , active infection additional concurrent condition would compromise patient 's ability safely receive rindopepimut vaccine therapy . The patient surgically sterile postmenopausal , , childbearing potential , negative serum pregnancy test within week prior initiation rindopepimut nursing . Males females childbearing potential must agree practice effective form contraception time sign informed consent 28 day last dose rindopepimut . The patient able read understand , sign patient inform consent form , outline anticipate benefit risk treatment rindopepimut .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>